Oragenics inc (OGEN)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
Assets
Current assets:
Cash and cash equivalents

14,372

18,267

22,291

25,719

29,348

20,208

13,811

3,940

4,757

6,166

2,923

2,088

2,175

4,080

5,116

5,457

3,367

5,083

6,738

8,043

9,053

10,448

11,764

12,898

14,638

16,276

8,267

6,367

8,350

9,925

11,757

1,130

967

171

-

0

132

Restricted cash

-

-

-

-

-

-

-

-

-

-

1,408

1,919

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Note receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

450

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25

61

144

195

294

264

382

440

475

Accounts receivables, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32

-

19

26

29

15

26

22

42

64

58

49

55

69

72

39

63

92

44

55

122

Income tax receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

362

Inventory, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

241

-

299

364

377

439

263

238

265

288

223

303

117

124

279

353

362

475

465

500

266

Prepaid expenses and other current assets

328

570

555

355

1,724

1,724

1,660

1,257

722

1,027

769

517

106

141

171

111

192

209

173

90

133

119

221

144

154

175

227

302

210

221

236

152

123

113

168

122

139

Current assets of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13

-

345

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total current assets

14,700

18,838

22,847

26,075

31,073

21,933

15,472

5,197

5,480

7,193

5,101

4,525

2,281

4,221

5,288

6,032

3,834

5,637

7,230

8,524

9,593

11,023

12,276

13,304

15,102

16,804

8,777

7,022

8,759

10,403

12,491

1,871

1,812

1,118

1,060

1,119

1,499

Property and equipment, net

79

91

89

101

103

116

63

10

13

21

34

51

69

87

107

104

122

140

159

170

167

109

26

31

39

26

38

48

63

84

92

111

129

148

168

188

228

Operating lease right-of-use assets

781

822

714

756

132

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total assets

15,562

19,752

23,651

26,932

31,308

22,049

15,535

5,208

5,494

7,214

5,135

4,577

2,350

4,309

5,395

6,137

3,957

5,778

7,389

8,695

9,761

11,132

12,303

13,336

15,141

16,831

8,815

7,071

8,822

10,488

12,583

1,982

1,941

1,266

1,229

1,307

1,727

Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable and accrued expenses

1,786

1,541

1,894

1,741

1,975

1,043

1,366

1,537

1,111

818

1,594

1,060

1,102

1,277

786

693

986

831

761

548

509

710

604

703

807

909

2,364

1,222

1,082

1,157

1,398

1,254

1,264

1,740

1,543

1,611

1,514

Short-term notes payable

70

143

-

-

-

124

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Short-term notes payable

-

-

217

12

77

-

190

20

67

80

128

22

62

66

111

34

78

63

109

34

79

64

109

35

80

64

108

142

67

47

88

35

71

53

104

65

98

Operating lease liabilities

167

165

135

140

132

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Current liabilities of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11

169

-

152

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible note payable to shareholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,000

5,000

-

-

-

-

-

-

1,956

-

-

-

-

-

-

7,500

6,000

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

-

15

17

17

21

25

38

50

18

23

23

24

50

265

85

145

152

161

115

13

Total current liabilities

2,025

1,850

2,247

1,893

2,185

1,167

1,556

1,558

1,179

898

1,722

1,083

1,165

1,343

909

897

1,083

1,047

5,886

5,601

605

796

739

777

938

992

4,452

1,387

1,173

1,256

1,752

1,375

1,481

9,446

7,809

1,792

1,626

Long-term liabilities:
Operating lease liabilities

627

670

586

616

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Note payable to shareholder

-

-

-

-

-

-

-

-

-

-

2,400

2,400

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative liability

-

-

-

-

-

-

-

-

-

-

-

588

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total long-term liabilities

627

670

586

616

-

-

-

-

-

-

2,400

2,988

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shareholders' equity:
Note payable to shareholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,056

-

-

-

-

-

Note payable to shareholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

773

-

-

4,500

2,000

Total liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,809

6,292

3,626

Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 and 9,417,000 Series A shares, 6,600,000 and 6,600,000 Series B shares, 133.483 and 113.941 Series C shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

7,174

6,513

6,513

6,513

6,513

6,100

6,813

6,100

6,100

6,309

1,245

482

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Common stock, $0.001 par value; 200,000,000 shares authorized; 46,124,803 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

46

46

46

46

46

29

18

6

5

4

49

49

49

4

49

49

40

39

36

36

36

36

36

36

36

35

30

27

27

27

27

16

12

5

5

5

5

Stock subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-

0

30

1,015

2,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

97,846

97,788

-

97,447

97,221

92,552

92,347

86,903

86,630

86,356

86,244

86,248

86,214

85,963

85,957

-

-

-

-

-

-

-

-

-

-

-

Additional paid-in capital

138,890

138,024

138,014

137,782

137,676

126,125

115,764

103,404

101,788

101,402

99,658

-

-

97,660

-

-

-

-

-

-

-

-

-

-

-

-

71,408

63,406

63,298

63,290

62,901

48,076

42,286

32,810

32,470

32,258

31,412

Accumulated deficit

-133,202

-127,352

-123,755

-119,918

-115,112

-111,373

-108,617

-105,860

-103,578

-101,400

-99,940

-97,872

-96,651

-94,669

-91,994

-90,031

-89,718

-87,655

-85,436

-83,572

-77,237

-75,944

-74,721

-73,691

-71,796

-70,155

-67,075

-57,750

-55,676

-54,086

-52,097

-49,541

-42,612

-40,995

-39,056

-37,249

-33,317

Total shareholders' equity

12,909

17,231

20,818

24,422

29,123

20,881

13,978

3,650

4,315

6,316

1,013

505

1,185

2,965

4,486

5,239

2,873

4,731

1,503

3,094

9,155

10,336

11,563

12,558

14,203

15,838

4,362

5,683

7,649

9,231

10,831

-1,448

-314

-8,179

-6,580

-4,985

-1,899

Total liabilities and shareholders' equity

15,562

19,752

23,651

26,932

31,308

22,049

15,535

5,208

5,494

7,214

5,135

4,577

2,350

4,309

5,395

6,137

3,957

5,778

7,389

8,695

9,761

11,132

12,303

13,336

15,141

16,831

8,815

7,071

8,822

10,488

12,583

1,982

1,941

1,266

1,229

1,307

1,727